A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.

Benjamin Musher(Baylor College of Medicine), Angelica Sara Ingrid Loskog(Uppsala University), Ann M. Leen(Baylor College of Medicine), Brandon G. Smaglo(The University of Texas MD Anderson Cancer Center), Gustav Ullenhag(Uppsala University), Benjamin Brenner(Rambam Health Care Campus), Amanda Brisco(University of South Florida), Nir Stanietzky(Baylor College of Medicine), Wasif M. Abidi(Baylor College of Medicine), Mohamed O. Othman(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), James Jing(Baylor College of Medicine), Bambj Grilley(Baylor College of Medicine), Jinyu Lu(Baylor College of Medicine), Kalpesh Patel(Baylor College of Medicine), Jessica Wenthe(Uppsala University), Emma Eriksson(Uppsala University), Eric K. Rowinsky
Journal of Clinical Oncology
February 1, 2020
Cited by 12


Related Papers